Preferences for Attachment Devices for Individuals with Lower-Limb Loss: A Discrete-Choice Study to Inform Regulatory Decisions [0.03%]
下肢截肢者假体连接装置的偏好：基于监管决策的信息离散选择研究
Leslie Wilson,Matthew Garibaldi,Ruben Vargas et al.
Leslie Wilson et al.
Objective. The patient's perspective in shared decision making has expanded to regulatory decision making for medical devices under the Food and Drug Administration's Patient Preference Initiative. Methods. Using choice-based conjoint (CBC)...
Decision Making about Localized Esophageal Cancer Treatment: An Observational Study on Variation in Clinicians' Communication Behavior [0.03%]
关于局部食管癌治疗的决策制定：一项有关医务人员交流行为变异性的观察研究
L F van de Water,G C Scholten,I Henselmans et al.
L F van de Water et al.
Background. For localized esophageal cancer, more than 1 curative treatment option is available. As these different options are associated with substantially different treatment outcomes, decision making can be complex. Moreover, treatment ...
Evaluation of a Decision Support Intervention for Adolescents and Young Adults Newly Diagnosed with Cancer: A Pilot Randomized Trial [0.03%]
一项针对新诊断癌症的青少年和年轻成人决策支持干预措施评估的试点随机试验
Lamia P Barakat,Shannon N Hammer,Yansong Wen et al.
Lamia P Barakat et al.
Background. Limited involvement in treatment-related decision making can affect adolescent and young adult (AYA) cancer outcomes and well-being. Information on developmentally consistent approaches to enhance involvement in and experiences ...
A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines [0.03%]
用于支持澳大利亚临床指南的代偿期肝硬化患者常规肝细胞癌监测卫生经济学评价
Joachim Worthington,Emily He,Michael Caruana et al.
Joachim Worthington et al.
Background. Liver cancer is the only cancer in Australia with rising incidence and mortality rates, despite the potential for early detection through surveillance of high-risk individuals. Hepatocellular carcinoma (HCC), the most common for...
A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States [0.03%]
美国弥漫性大B细胞淋巴瘤治疗途径的成本效益分析
Anik R Patel,Bradley Kievit,Ken Hasegawa et al.
Anik R Patel et al.
Background. Chimeric antigen receptor (CAR) T-cell therapies are approved as second-line (2L) or later therapy for diffuse large B-cell lymphoma (DLBCL). Recently, bispecific T-cell antibodies (BsAbs) have been approved as third-line (3L) t...
Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study [0.03%]
探索肝细胞癌治疗决策中患者偏好的作用：一项定性研究
Andrew M Moon,Daniel Richardson,Gabriel V Lupu et al.
Andrew M Moon et al.
Background. Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient-provid...
The Impact of Alternative Specifications of Uncertainty Relating to Extrapolation in Decision Models [0.03%]
关于决策模型外推不确定性的替代规范的影响
Doug Coyle,Kathryn Coyle
Doug Coyle
Economic evaluations that incorporate value-of-information analysis frequently conclude that the greatest information value relates to replicating short-term clinical trials. This study builds on recent guidance relating to extrapolation in...
Characterizing the Design of and Emerging Evidence for Health Care Organization-Based Lung Cancer Screening Interventions: A Systematic Review [0.03%]
基于卫生保健机构的肺癌筛查干预设计及新兴证据的系统评价研究特征
Jennifer Elston Lafata,Katharine A Rendle,Jocelyn V Wainwright et al.
Jennifer Elston Lafata et al.
Background. Implementing a lung cancer screening (LCS) program with low-dose computed tomography (LDCT) is complex, requiring health care organizations to consider several steps along the screening continuum from eligibility assessment to r...
Primary Care Provider Preferences Regarding Artificial Intelligence in Point-of-Care Cancer Screening [0.03%]
关于人工智能在癌症筛查现场护理中的应用.Primary Care Providers的偏好调查
Vinayak S Ahluwalia,Marilyn M Schapira,Gary E Weissman et al.
Vinayak S Ahluwalia et al.
Background. It is unclear how to optimize the user interface and user experience of cancer screening artificial intelligence (AI) tools for clinical decision-making in primary care. Methods. We developed an electronic survey for US primary ...
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan [0.03%]
台湾慢性乙肝患者使用Tenofovir Alafenamide的成本效果分析
Elise Chia-Hui Tan,Alon Yehoshua,Sushanth Jeyakumar et al.
Elise Chia-Hui Tan et al.
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim. This analysis asse...